Biopharmaceutical company founded in 2017 developing subcutaneous drug-delivery platforms for pain management and mental health. Its lead candidate BB106 is a proprietary ketamine formulation delivered through a wearable subcutaneous patch pump developed with Stevanato Group, targeting indications including treatment-resistant depression. The company is also applying its delivery technology to psychedelic and empathogen compounds.